{"id":"NCT02512068","sponsor":"Takeda","briefTitle":"A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study to Evaluate the Efficacy and Safety of SYR-472 When Orally Administered at a Dose of 25 mg Once Weekly in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-07","primaryCompletion":"2018-04-24","completion":"2018-04-24","firstPosted":"2015-07-30","resultsPosted":"2019-11-04","lastUpdate":"2023-12-12"},"enrollment":107,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Trelagliptin 25 mg","otherNames":["SYR-472"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Trelagliptin 25 mg","type":"EXPERIMENTAL"},{"label":"Placebo and Trelagliptin 25 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of trelagliptin when administered at a dose of 25 mg once weekly using placebo as a control in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal disease and inadequate glycemic control despite diet and/or exercise therapy (if given) or despite treatment with one antidiabetic drug in addition to diet and/or exercise therapy (if given); and to evaluate the long-term efficacy and safety of trelagliptin when administered at a dose of 25 mg once weekly to patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal disease.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at the End of Treatment Period I","timeFrame":"Baseline (Week 0) and end of Treatment Period I (Up to Week 12)","effectByArm":[{"arm":"Trelagliptin 25 mg","deltaMin":-0.71,"sd":0.087},{"arm":"Placebo and Trelagliptin 25 mg","deltaMin":0.01,"sd":0.089}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":49,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":55},"commonTop":["Nasopharyngitis","Hypoglycaemia","Fall","Contusion","Diarrhoea"]}}